

For further information, contact:

Dr. Robert B. Harris

President/CEO, CBI

Phone: 800 735 9224

Fax: 804 648 2641

Commonwealth Biotechnologies, Inc. to Present at the Wall Street Analyst Forum

RICHMOND, VA (May 30, 2006) - Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE), today announced that Dr. Robert B. Harris, President and CEO and Dr. Richard J. Freer, Chair and COO, have been invited to present a corporate overview Wednesday, June 14 at 8:30 AM during the Biotechnology and Special Pharma session of the Wall Street Analyst's Forum's (WSAF) 17th Annual Analyst Conference, taking place at the Princeton Club in New York City. The WSAF caters to buy side and sell side-analysts and portfolio managers. Dr. Harris' presentation will be webcast live from the Forum and interested parties may access the webcast from the link to be posted to CBI's webpage at www.cbi-biotech.com. The presentation slides will also be posted to the Company's webpage a few days after June 14th.

About CBI

Commonwealth Biotechnologies, Inc. is a solutions provider to the global biotechnology industry, academic institutions, government agencies, and pharmaceutical companies. It offers broad ranging expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. CBI has crafted a stimulating, open environment where scientists collaborate among themselves and with our clients, take on interesting challenges and develop creative solutions. Through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS

analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3 laboratory. For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities.